- Home
- ANEB vs MRSN Comparison
ANEB vs MRSN Comparison
Compare ANEB & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- MRSN
- Stock Information
- Founded
- ANEB 2020
- MRSN 2001
- Country
- ANEB United States
- MRSN United States
- Employees
- ANEB N/A
- MRSN N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- MRSN Health Care
- Exchange
- ANEB Nasdaq
- MRSN Nasdaq
- Market Cap
- ANEB 39.0M
- MRSN 40.7M
- IPO Year
- ANEB 2021
- MRSN 2017
- Fundamental
- Price
- ANEB $1.06
- MRSN $0.37
- Analyst Decision
- ANEB Strong Buy
- MRSN Strong Buy
- Analyst Count
- ANEB 2
- MRSN 5
- Target Price
- ANEB $5.50
- MRSN $5.75
- AVG Volume (30 Days)
- ANEB 11.6K
- MRSN 3.1M
- Earning Date
- ANEB 05-13-2025
- MRSN 05-15-2025
- Dividend Yield
- ANEB N/A
- MRSN N/A
- EPS Growth
- ANEB N/A
- MRSN N/A
- EPS
- ANEB N/A
- MRSN N/A
- Revenue
- ANEB N/A
- MRSN $34,006,000.00
- Revenue This Year
- ANEB N/A
- MRSN N/A
- Revenue Next Year
- ANEB N/A
- MRSN N/A
- P/E Ratio
- ANEB N/A
- MRSN N/A
- Revenue Growth
- ANEB N/A
- MRSN N/A
- 52 Week Low
- ANEB $0.80
- MRSN $0.26
- 52 Week High
- ANEB $3.08
- MRSN $2.83
- Technical
- Relative Strength Index (RSI)
- ANEB 47.21
- MRSN 51.71
- Support Level
- ANEB $1.00
- MRSN $0.33
- Resistance Level
- ANEB $1.15
- MRSN $0.38
- Average True Range (ATR)
- ANEB 0.07
- MRSN 0.04
- MACD
- ANEB 0.01
- MRSN 0.00
- Stochastic Oscillator
- ANEB 44.49
- MRSN 58.60
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.